Public Company Healthcare

Takeda

Tokyo, Tokyo, Japan

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company advancing potentially life-changing treatments. Its therapeutic focus areas include oncology, rare diseases, neuroscience, gastroenterology, immune-mediated diseases, and plasma-derived therapies and vaccines.

Focus Areas
Biopharmaceuticals, Oncology, Rare Diseases
Website
takeda.com

Tracked deals

3

3 tracked deals across 2020-2023.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

Takeda Acquisition Volume by Year

Last 3 years

Acquisition volume by year Annual acquisition counts for the last 3 years for Takeda. 1 2020 1 2021 1 2023

Supporting Data

Recent Transactions

  • Takeda Acquires Nimbus Therapeutics' TYK2 Program Subsidiary (Nimbus Lakshmi)
    February 8, 2023
    Buyer
    Takeda Pharmaceutical Company Limited
    Target
    Nimbus Lakshmi, Inc.
    Seller
    Nimbus Therapeutics, LLC
    Industry
    Pharmaceuticals
    Location
    Massachusetts, United States
    Type
    Buyout

    Takeda Pharmaceutical Company Limited has completed the acquisition of all shares of Nimbus Lakshmi, Inc. (the TYK2 program subsidiary of Nimbus Therapeutics) for approximately $4.0 billion upfront, with up to $2.0 billion in potential milestone payments. The deal adds TAK-279 (NDI-034858), a selective oral TYK2 inhibitor moving into late‑stage development, strengthening Takeda's late‑stage pipeline in immune‑mediated diseases including psoriasis and other immunological indications.

  • Takeda Pharmaceutical Company Limited Acquires Maverick Therapeutics, Inc.
    March 9, 2021
    Buyer
    Takeda Pharmaceutical Company Limited
    Target
    Maverick Therapeutics, Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Takeda exercised its option to acquire Maverick Therapeutics, obtaining Maverick's COBRA conditionally active bispecific T‑cell engager platform and lead development candidates (TAK‑186 and TAK‑280). The deal, based on a prior collaboration and equity stake, is structured for up to $525 million in upfront and potential milestone payments and will fold Maverick's R&D team into Takeda's organization.

  • Takeda Pharmaceutical Acquires PvP Biologics
    February 26, 2020
    Buyer
    Takeda Pharmaceutical Company Limited
    Target
    PvP Biologics, Inc.
    Industry
    Biotechnology
    Location
    Washington, United States
    Type
    Buyout

    Takeda Pharmaceutical Company Limited exercised its option to acquire PvP Biologics, Inc. following positive Phase 1 proof-of-mechanism results for TAK-062 (Kuma062), an oral engineered glutenase for celiac disease. The deal includes a pre-negotiated upfront payment and up to $330 million in development and regulatory milestones and brings TAK-062 and TAK-101 into Takeda's gastroenterology pipeline.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 2 tracked deals by Takeda. Pharmaceuticals Buyers & Acquisitions 1 tracked deal by Takeda. Acquisitions in California 1 tracked deal by Takeda. Acquisitions in Massachusetts 1 tracked deal by Takeda. Acquisitions in Washington 1 tracked deal by Takeda.

Related articles

Selling a company? Get in front of buyers like Takeda

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →